Sumitomo sues over antipsychotic drug
14-02-2018
Tibor Duris / Shutterstock.com
Par Pharmaceutical has sought a declaratory judgment that it did not infringe patents belonging to Sumitomo and its subsidiary Sunovion that protect bipolar disorder drug Latuda (lurasidone hydrochloride).
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
patent, patent infringement, Par Pharmaceutical, Sunovion Pharmaceuticals, Sumitomo Dainippon Pharma, declaratory judgment, ANDA, generics